查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2040362

小分子原料藥/CDMO市場規模、佔有率和趨勢分析報告：按藥物、應用、最終用途、地區和細分市場分類（2026-2033年）

Small Molecule API CDMO Market Size, Share & Trends Analysis Report By Drug, By Application, By End Use, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 200 Pages | 商品交期: 2-10個工作天內

價格

低分子量原料藥CDMO市場概述

2025年全球小分子API/CDMO市值為465.9億美元，預計2033年將達到807.4億美元，2026年至2033年的複合年成長率為7.28%。

推動市場成長的因素包括：對複雜 API 和先進製造能力的需求不斷成長，加強地緣政治變化和供應鏈韌性的努力不斷增加，永續性和綠色化學的日益普及，以及數位化、人工智慧的融合和不斷變化的法規環境等方面的進步。

小分子原料藥（API）的日益複雜化，包括多步驟合成、掌性化學和高活性化合物，正在推動對專業CDMO（合約研發生產機構）能力的需求。製藥公司正大規模地將部分生產外包給擁有先進生產技術、安全防護設施和符合監管要求的合作公司。這一點在不斷擴充的高活性原料藥（HPAPI）和用於癌症治療及標靶治療的複雜小分子化合物的研發管線中尤為明顯。此外，對創新治療方法日益成長的需求也加速了對擁有先進安全防護技術和專業製程開發能力的CDMO的需求。隨著藥物分子結構變得越來越複雜，能夠提供從早期研發到商業化生產一體化服務的CDMO正在獲得競爭優勢。

此外，全球地緣政治格局的變化正在重塑醫藥供應鏈，韌性、在地化和供應穩定性日益受到重視。各國政府正在實施法律措施，以減少對海外原料藥的依賴，尤其是在關鍵藥物類別方面。例如，美國於2024年9月通過的《生物安全法案》鼓勵基本藥物的國內生產，這為擁有強大本地實力或能夠滿足嚴格採購要求的合約研發生產機構（CDMO）創造了新的機會。這種轉變促使製藥公司實現供應商多元化，並投資與本地CDMO建立合作關係。此外，加強品管系統和監管合規框架對於防止供應中斷也變得至關重要。

此外，在監管壓力和不斷變化的客戶期望的雙重驅動下，永續性正成為市場的重要促進因素。製藥公司正優先考慮環保的生產實踐，包括綠色化學、減少廢棄物和節能製程。區域監管機構正在實施更嚴格的環境準則，迫使合約研發生產機構（CDMO）採用永續技術並減少碳足跡。這包括使用更安全的溶劑、實施連續生產技術以及提高製程效率以最大限度地減少對環境的影響。此外，客戶在選擇CDMO合作夥伴時，會優先考慮其對永續性的承諾，這使其成為競爭性競標中的關鍵差異化因素。

目錄

第1章 研究方法和範圍

第2章執行摘要

第3章：小分子原料藥CDMO市場：變數、趨勢與範圍

  • 市場譜系展望
  • 市場動態
  • 科技情勢
  • 定價模式分析
  • 關稅影響分析
  • 價值鏈分析
  • 市場分析工具

第4章：小分子原料藥CDMO市場：依藥物類型分類的估算與趨勢分析

  • 小分子原料藥CDMO市場：按藥物類型分類的波動分析
  • 小分子原料藥CDMO市場：依藥物類型分類的估算與預測，2021-2033年
  • 創新者
  • 學名藥

第5章 小分子原料藥CDMO市場：依應用領域分類的估算與趨勢分析

  • 低分子量原料藥/CDMO市場：基於應用的波動分析
  • 小分子原料藥/CDMO市場：按應用領域分類的估算與預測，2021-2033年
  • 心血管疾病
  • 腫瘤學
  • 呼吸系統疾病
  • 神經病學
  • 代謝性疾病
  • 感染疾病
  • 其他

第6章：低分子量原料藥/CDMO市場：依最終用途分類的估算與趨勢分析

  • 低分子量原料藥/CDMO市場：依最終用途及波動情況分析
  • 小分子原料藥/CDMO市場：依最終用途分類的估算與預測，2021-2033年
  • 製藥
    • Small
    • 中等的
    • 大的
  • 生物技術
    • Small
    • 中等的
    • 大的

第7章 小分子原料藥CDMO市場：區域估算與趨勢分析

  • 區域市場概覽
  • 2025年及2033年區域市佔率分析
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 泰國
    • 韓國
    • 澳洲
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • UAE
    • 科威特
    • 阿曼
    • 卡達

第8章 競爭情勢

  • 主要公司分類
    • Market Leaders
    • Emerging Players
  • 2025年市佔率及估值分析（熱圖分析）
  • 公司簡介
    • Lonza Group
    • Catalent
    • Thermo Fisher Scientific
    • WuXi AppTec
    • Siegfried Holding AG
    • Cambrex Corporation
    • Recipharm
    • CordenPharma
    • Ajinomoto Bio-Pharma Services
    • Curia
    • Piramal Pharma Solutions
    • Jubilant Biosys
    • Syngene International
    • Neuland Laboratories
    • Axplora
Product Code: GVR-4-68040-899-2

Small Molecule API CDMO Market Summary

The global small molecule API CDMO market size was valued at USD 46.59 billion in 2025 and is projected to reach USD 80.74 billion by 2033, growing at a CAGR of 7.28% from 2026 to 2033. The market is experiencing growth driven by rising demand for complex APIs and advanced manufacturing capabilities, increasing geopolitical shifts and supply chain resilience initiatives, sustainability, and rising green chemistry adoption, and increasing digitalization, AI integration, and regulatory evolution.

The increasing complexity of small-molecule APIs, including multi-step synthesis, chiral chemistry, and high-potency compounds, is driving demand for specialized CDMO capabilities. Pharmaceutical companies are outsourcing in large numbers to partners with advanced manufacturing expertise, containment infrastructure, and regulatory-compliant facilities. This is particularly evident in the growing pipeline of highly potent APIs (HPAPIs) and complex small molecules used in oncology and targeted therapies. In addition, the growing demand for innovative therapies is accelerating the need for CDMOs equipped with high-containment technologies and specialized process development capabilities. As drug molecules become more structurally sophisticated, CDMOs offering integrated services from early-stage development to commercial-scale manufacturing are gaining a competitive edge.

In addition, global geopolitical changes are transforming pharmaceutical supply chains, driving greater emphasis on resilience, localization, and supply security. Governments are introducing legislative measures to reduce dependency on foreign API sources, particularly in critical drug categories. For instance, the Biosecure Act, passed in September 2024 in the U.S., is encouraging domestic manufacturing of essential drugs, creating new opportunities for CDMOs with a strong regional presence or the ability to comply with stringent sourcing requirements. This shift is prompting pharmaceutical companies to diversify suppliers and invest in regionally aligned CDMO partnerships. In addition, enhanced quality systems and regulatory compliance frameworks are becoming essential to ensure uninterrupted supply.

Furthermore, sustainability is emerging as a critical driver in the market, influenced by both regulatory pressures and evolving customer expectations. Pharmaceutical companies are prioritizing environmentally responsible manufacturing practices, including green chemistry, waste reduction, and energy-efficient processes. The regulatory bodies across regions are implementing stricter environmental guidelines, compelling CDMOs to adopt sustainable technologies and reduce their carbon footprint. This includes the use of safer solvents, continuous manufacturing techniques, and improved process efficiency to minimize environmental impact. In addition, clients are selecting CDMO partners based on their sustainability credentials, making it a key differentiator in competitive bidding.

Global Small Molecule API CDMO Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global small molecule API CDMO market report based on drug, application, end use, and region:

  • Drug Outlook (Revenue, USD Million, 2021 - 2033)
  • Innovators
  • Generics
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Cardiovascular Diseases
  • Oncology
  • Respiratory Disorders
  • Neurology
  • Metabolic Disorders
  • Infectious Diseases
  • Others
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Pharmaceutical
    • Small
    • Medium
    • Large
  • Biotechnology
    • Small
    • Medium
    • Large
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait
    • Oman
    • Qatar

Table of Contents

Chapter 1. Research Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug
    • 1.2.2. Application
    • 1.2.3. End Use
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Information Or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity Flow Analysis
    • 1.7.2. Top-Down Analysis
    • 1.7.3. Bottom-Up Approach
    • 1.7.4. Multivariate Analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Abbreviations
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Small Molecule API CDMO Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing Demand for Small Molecule Drugs
      • 3.2.1.2. Increasing Outsourcing Trends Among Pharmaceutical Companies
      • 3.2.1.3. Surge in Number of Clinical Trials
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Compliance Issues While Outsourcing
      • 3.2.2.2. Changing Scenarios in Developing Economies
  • 3.3. Technology Landscape
  • 3.4. Pricing Model Analysis
  • 3.5. Tariff Impact Analysis
  • 3.6. Value Chain Analysis
    • 3.6.1. Supply Trends
    • 3.6.2. Demand Trends
  • 3.7. Market Analysis Tools
    • 3.7.1. Porter's Five Force Analysis
    • 3.7.2. PESTEL by SWOT Analysis

Chapter 4. Small Molecule API CDMO Market: Drug Estimates & Trend Analysis

  • 4.1. Small Molecule API CDMO Market, By Drug: Segment Dashboard
  • 4.2. Small Molecule API CDMO Market, By Drug: Movement Analysis
  • 4.3. Small Molecule API CDMO Market Estimates & Forecasts, By Drug, 2021 - 2033
  • 4.4. Innovators
    • 4.4.1. Innovators Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Generics
    • 4.5.1. Generics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Small Molecule API CDMO Market: Application Estimates & Trend Analysis

  • 5.1. Small Molecule API CDMO Market, By Application: Segment Dashboard
  • 5.2. Small Molecule API CDMO Market, By Application: Movement Analysis
  • 5.3. Small Molecule API CDMO Market Estimates & Forecasts, By Application, 2021 - 2033
  • 5.4. Cardiovascular Diseases
    • 5.4.1. Cardiovascular Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Oncology
    • 5.5.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6. Respiratory Disorders
    • 5.6.1. Respiratory Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.7. Neurology
    • 5.7.1. Neurology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.8. Metabolic Disorders
    • 5.8.1. Metabolic Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.9. Infectious Diseases
    • 5.9.1. Infectious Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.10. Others
    • 5.10.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Small Molecule API CDMO Market: End Use Estimates & Trend Analysis

  • 6.1. Small Molecule API CDMO Market, By End Use: Segment Dashboard
  • 6.2. Small Molecule API CDMO Market, By End Use: Movement Analysis
  • 6.3. Small Molecule API CDMO Market Estimates & Forecasts, By End Use, 2021 - 2033
  • 6.4. Pharmaceutical
    • 6.4.1. Pharmaceutical Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.2. Small
      • 6.4.2.1. Small Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.3. Medium
      • 6.4.3.1. Medium Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.4. Large
      • 6.4.4.1. Large Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Biotechnology
    • 6.5.1. Biotechnology Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.2. Small
      • 6.5.2.1. Small Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.3. Medium
      • 6.5.3.1. Medium Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.4. Large
      • 6.5.4.1. Large Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Small Molecule API CDMO Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Dashboard
  • 7.2. Regional Market Share Analysis, 2025 & 2033
  • 7.3. North America
    • 7.3.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.2. U.S
      • 7.3.2.1. Key Country Dynamics
      • 7.3.2.2. Competitive Scenario
      • 7.3.2.3. Regulatory Framework
      • 7.3.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.3. Canada
      • 7.3.3.1. Key Country Dynamics
      • 7.3.3.2. Competitive Scenario
      • 7.3.3.3. Regulatory Framework
      • 7.3.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.4. Mexico
      • 7.3.4.1. Key Country Dynamics
      • 7.3.4.2. Competitive Scenario
      • 7.3.4.3. Regulatory Framework
      • 7.3.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4. Europe
    • 7.4.1. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.2. UK
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Competitive Scenario
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. UK Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.3. Germany
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Competitive Scenario
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.4. France
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Competitive Scenario
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.5. Italy
      • 7.4.5.1. Key Country Dynamics
      • 7.4.5.2. Competitive Scenario
      • 7.4.5.3. Regulatory Framework
      • 7.4.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.6. Spain
      • 7.4.6.1. Key Country Dynamics
      • 7.4.6.2. Competitive Scenario
      • 7.4.6.3. Regulatory Framework
      • 7.4.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.7. Denmark
      • 7.4.7.1. Key Country Dynamics
      • 7.4.7.2. Competitive Scenario
      • 7.4.7.3. Regulatory Framework
      • 7.4.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.8. Sweden
      • 7.4.8.1. Key Country Dynamics
      • 7.4.8.2. Competitive Scenario
      • 7.4.8.3. Regulatory Framework
      • 7.4.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.9. Norway
      • 7.4.9.1. Key Country Dynamics
      • 7.4.9.2. Competitive Scenario
      • 7.4.9.3. Regulatory Framework
      • 7.4.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.2. Japan
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Competitive Scenario
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.3. China
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Competitive Scenario
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.4. India
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Competitive Scenario
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.5. Thailand
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Competitive Scenario
      • 7.5.5.3. Regulatory Framework
      • 7.5.5.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.6. South Korea
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Competitive Scenario
      • 7.5.6.3. Regulatory Framework
      • 7.5.6.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.7. Australia
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Competitive Scenario
      • 7.5.7.3. Regulatory Framework
      • 7.5.7.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.2. Brazil
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Competitive Scenario
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.3. Argentina
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Competitive Scenario
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7. MEA
    • 7.7.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.2. South Africa
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Competitive Scenario
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.3. Saudi Arabia
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Competitive Scenario
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.4. UAE
      • 7.7.4.1. Key Country Dynamics
      • 7.7.4.2. Competitive Scenario
      • 7.7.4.3. Regulatory Framework
      • 7.7.4.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.5. Kuwait
      • 7.7.5.1. Key Country Dynamics
      • 7.7.5.2. Competitive Scenario
      • 7.7.5.3. Regulatory Framework
      • 7.7.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.6. Oman
      • 7.7.6.1. Key Country Dynamics
      • 7.7.6.2. Competitive Scenario
      • 7.7.6.3. Regulatory Framework
      • 7.7.6.4. Oman Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.7. Qatar
      • 7.7.7.1. Key Country Dynamics
      • 7.7.7.2. Competitive Scenario
      • 7.7.7.3. Regulatory Framework
      • 7.7.7.4. Qatar Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Key Participant Categorization
    • 8.1.1. Market Leaders
    • 8.1.2. Emerging Players
  • 8.2. Market Share/Assessment Analysis, 2025 (Heat Map Analysis)
  • 8.3. Company Profiles
    • 8.3.1. Lonza Group
      • 8.3.1.1. Company Overview
      • 8.3.1.2. Financial Performance
      • 8.3.1.3. Service Benchmarking
      • 8.3.1.4. Strategic Initiatives
    • 8.3.2. Catalent
      • 8.3.2.1. Company Overview
      • 8.3.2.2. Financial Performance
      • 8.3.2.3. Service Benchmarking
      • 8.3.2.4. Strategic Initiatives
    • 8.3.3. Thermo Fisher Scientific
      • 8.3.3.1. Company Overview
      • 8.3.3.2. Financial Performance
      • 8.3.3.3. Service Benchmarking
      • 8.3.3.4. Strategic Initiatives
    • 8.3.4. WuXi AppTec
      • 8.3.4.1. Company Overview
      • 8.3.4.2. Financial Performance
      • 8.3.4.3. Service Benchmarking
      • 8.3.4.4. Strategic Initiatives
    • 8.3.5. Siegfried Holding AG
      • 8.3.5.1. Company Overview
      • 8.3.5.2. Financial Performance
      • 8.3.5.3. Service Benchmarking
      • 8.3.5.4. Strategic Initiatives
    • 8.3.6. Cambrex Corporation
      • 8.3.6.1. Company Overview
      • 8.3.6.2. Financial Performance
      • 8.3.6.3. Service Benchmarking
      • 8.3.6.4. Strategic Initiatives
    • 8.3.7. Recipharm
      • 8.3.7.1. Company Overview
      • 8.3.7.2. Financial Performance
      • 8.3.7.3. Service Benchmarking
      • 8.3.7.4. Strategic Initiatives
    • 8.3.8. CordenPharma
      • 8.3.8.1. Company Overview
      • 8.3.8.2. Financial Performance
      • 8.3.8.3. Service Benchmarking
      • 8.3.8.4. Strategic Initiatives
    • 8.3.9. Ajinomoto Bio-Pharma Services
      • 8.3.9.1. Company Overview
      • 8.3.9.2. Financial Performance
      • 8.3.9.3. Service Benchmarking
      • 8.3.9.4. Strategic Initiatives
    • 8.3.10. Curia
      • 8.3.10.1. Company Overview
      • 8.3.10.2. Financial Performance
      • 8.3.10.3. Service Benchmarking
      • 8.3.10.4. Strategic Initiatives
    • 8.3.11. Piramal Pharma Solutions
      • 8.3.11.1. Company Overview
      • 8.3.11.2. Financial Performance
      • 8.3.11.3. Service Benchmarking
      • 8.3.11.4. Strategic Initiatives
    • 8.3.12. Jubilant Biosys
      • 8.3.12.1. Company Overview
      • 8.3.12.2. Financial Performance
      • 8.3.12.3. Service Benchmarking
      • 8.3.12.4. Strategic Initiatives
    • 8.3.13. Syngene International
      • 8.3.13.1. Company Overview
      • 8.3.13.2. Financial Performance
      • 8.3.13.3. Service Benchmarking
      • 8.3.13.4. Strategic Initiatives
    • 8.3.14. Neuland Laboratories
      • 8.3.14.1. Company Overview
      • 8.3.14.2. Financial Performance
      • 8.3.14.3. Service Benchmarking
      • 8.3.14.4. Strategic Initiatives
    • 8.3.15. Axplora
      • 8.3.15.1. Company Overview
      • 8.3.15.2. Financial Performance
      • 8.3.15.3. Service Benchmarking
      • 8.3.15.4. Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Small Molecule API CDMO Market, by Drug, 2021 - 2033 (USD Million)
  • Table 4 Global Small Molecule API CDMO Market, by Application, 2021 - 2033 (USD Million)
  • Table 5 Global Small Molecule API CDMO Market, by End Use, 2021 - 2033 (USD Million)
  • Table 6 Global Small Molecule API CDMO Market, by Region, 2021 - 2033 (USD Million)
  • Table 7 North America Small Molecule API CDMO Market, by Country, 2021 - 2033 (USD Million)
  • Table 8 North America Small Molecule API CDMO Market, by Drug, 2021 - 2033 (USD Million)
  • Table 9 North America Small Molecule API CDMO Market, by Application, 2021 - 2033 (USD Million)
  • Table 10 North America Small Molecule API CDMO Market, by End Use, 2021 - 2033 (USD Million)
  • Table 11 U.S. Small Molecule API CDMO Market, by Drug, 2021 - 2033 (USD Million)
  • Table 12 U.S. Small Molecule API CDMO Market, by Application, 2021 - 2033 (USD Million)
  • Table 13 U.S. Small Molecule API CDMO Market, by End Use, 2021 - 2033 (USD Million)
  • Table 14 Canada Small Molecule API CDMO Market, by Drug, 2021 - 2033 (USD Million)
  • Table 15 Canada Small Molecule API CDMO Market, by Application, 2021 - 2033 (USD Million)
  • Table 16 Canada Small Molecule API CDMO Market, by End Use, 2021 - 2033 (USD Million)
  • Table 17 Mexico Small Molecule API CDMO Market, by Drug, 2021 - 2033 (USD Million)
  • Table 18 Mexico Small Molecule API CDMO Market, by Application, 2021 - 2033 (USD Million)
  • Table 19 Mexico Small Molecule API CDMO Market, by End Use, 2021 - 2033 (USD Million)
  • Table 20 Europe Small Molecule API CDMO Market, by Country, 2021 - 2033 (USD Million)
  • Table 21 Europe Small Molecule API CDMO Market, by Drug, 2021 - 2033 (USD Million)
  • Table 22 Europe Small Molecule API CDMO Market, by Application, 2021 - 2033 (USD Million)
  • Table 23 Europe Small Molecule API CDMO Market, by End Use, 2021 - 2033 (USD Million)
  • Table 24 UK Small Molecule API CDMO Market, by Drug, 2021 - 2033 (USD Million)
  • Table 25 UK Small Molecule API CDMO Market, by Application, 2021 - 2033 (USD Million)
  • Table 26 UK Small Molecule API CDMO Market, by End Use, 2021 - 2033 (USD Million)
  • Table 27 Germany Small Molecule API CDMO Market, by Drug, 2021 - 2033 (USD Million)
  • Table 28 Germany Small Molecule API CDMO Market, by Application, 2021 - 2033 (USD Million)
  • Table 29 Germany Small Molecule API CDMO Market, by End Use, 2021 - 2033 (USD Million)
  • Table 30 France Small Molecule API CDMO Market, by Drug, 2021 - 2033 (USD Million)
  • Table 31 France Small Molecule API CDMO Market, by Application, 2021 - 2033 (USD Million)
  • Table 32 France Small Molecule API CDMO Market, by End Use, 2021 - 2033 (USD Million)
  • Table 33 Italy Small Molecule API CDMO Market, by Drug, 2021 - 2033 (USD Million)
  • Table 34 Italy Small Molecule API CDMO Market, by Application, 2021 - 2033 (USD Million)
  • Table 35 Italy Small Molecule API CDMO Market, by End Use, 2021 - 2033 (USD Million)
  • Table 36 Spain Small Molecule API CDMO Market, by Drug, 2021 - 2033 (USD Million)
  • Table 37 Spain Small Molecule API CDMO Market, by Application, 2021 - 2033 (USD Million)
  • Table 38 Spain Small Molecule API CDMO Market, by End Use, 2021 - 2033 (USD Million)
  • Table 39 Denmark Small Molecule API CDMO Market, by Drug, 2021 - 2033 (USD Million)
  • Table 40 Denmark Small Molecule API CDMO Market, by Application, 2021 - 2033 (USD Million)
  • Table 41 Denmark Small Molecule API CDMO Market, by End Use, 2021 - 2033 (USD Million)
  • Table 42 Sweden Small Molecule API CDMO Market, by Drug, 2021 - 2033 (USD Million)
  • Table 43 Sweden Small Molecule API CDMO Market, by Application, 2021 - 2033 (USD Million)
  • Table 44 Sweden Small Molecule API CDMO Market, by End Use, 2021 - 2033 (USD Million)
  • Table 45 Norway Small Molecule API CDMO Market, by Drug, 2021 - 2033 (USD Million)
  • Table 46 Norway Small Molecule API CDMO Market, by Application, 2021 - 2033 (USD Million)
  • Table 47 Norway Small Molecule API CDMO Market, by End Use, 2021 - 2033 (USD Million)
  • Table 48 Asia Pacific Small Molecule API CDMO Market, by Country, 2021 - 2033 (USD Million)
  • Table 49 Asia Pacific Small Molecule API CDMO Market, by Drug, 2021 - 2033 (USD Million)
  • Table 50 Asia Pacific Small Molecule API CDMO Market, by Application, 2021 - 2033 (USD Million)
  • Table 51 Asia Pacific Small Molecule API CDMO Market, by End Use, 2021 - 2033 (USD Million)
  • Table 52 China Small Molecule API CDMO Market, by Drug, 2021 - 2033 (USD Million)
  • Table 53 China Small Molecule API CDMO Market, by Application, 2021 - 2033 (USD Million)
  • Table 54 China Small Molecule API CDMO Market, by End Use, 2021 - 2033 (USD Million)
  • Table 55 Japan Small Molecule API CDMO Market, by Drug, 2021 - 2033 (USD Million)
  • Table 56 Japan Small Molecule API CDMO Market, by Application, 2021 - 2033 (USD Million)
  • Table 57 Japan Small Molecule API CDMO Market, by End Use, 2021 - 2033 (USD Million)
  • Table 58 India Small Molecule API CDMO Market, by Drug, 2021 - 2033 (USD Million)
  • Table 59 India Small Molecule API CDMO Market, by Application, 2021 - 2033 (USD Million)
  • Table 60 India Small Molecule API CDMO Market, by End Use, 2021 - 2033 (USD Million)
  • Table 61 Australia Small Molecule API CDMO Market, by Drug, 2021 - 2033 (USD Million)
  • Table 62 Australia Small Molecule API CDMO Market, by Application, 2021 - 2033 (USD Million)
  • Table 63 Australia Small Molecule API CDMO Market, by End Use, 2021 - 2033 (USD Million)
  • Table 64 South Korea Small Molecule API CDMO Market, by Drug, 2021 - 2033 (USD Million)
  • Table 65 South Korea Small Molecule API CDMO Market, by Application, 2021 - 2033 (USD Million)
  • Table 66 South Korea Small Molecule API CDMO Market, by End Use, 2021 - 2033 (USD Million)
  • Table 67 Thailand Small Molecule API CDMO Market, by Drug, 2021 - 2033 (USD Million)
  • Table 68 Thailand Small Molecule API CDMO Market, by Application, 2021 - 2033 (USD Million)
  • Table 69 Thailand Small Molecule API CDMO Market, by End Use, 2021 - 2033 (USD Million)
  • Table 70 Latin America Small Molecule API CDMO Market, by Country, 2021 - 2033 (USD Million)
  • Table 71 Latin America Small Molecule API CDMO Market, by Drug, 2021 - 2033 (USD Million)
  • Table 72 Latin America Small Molecule API CDMO Market, by Application, 2021 - 2033 (USD Million)
  • Table 73 Latin America Small Molecule API CDMO Market, by End Use, 2021 - 2033 (USD Million)
  • Table 74 Brazil Small Molecule API CDMO Market, by Drug, 2021 - 2033 (USD Million)
  • Table 75 Brazil Small Molecule API CDMO Market, by Application, 2021 - 2033 (USD Million)
  • Table 76 Brazil Small Molecule API CDMO Market, by End Use, 2021 - 2033 (USD Million)
  • Table 77 Argentina Small Molecule API CDMO Market, by Drug, 2021 - 2033 (USD Million)
  • Table 78 Argentina Small Molecule API CDMO Market, by Application, 2021 - 2033 (USD Million)
  • Table 79 Argentina Small Molecule API CDMO Market, by End Use, 2021 - 2033 (USD Million)
  • Table 80 Middle East & Africa Small Molecule API CDMO Market, by Country, 2021 - 2033 (USD Million)
  • Table 81 Middle East & Africa Small Molecule API CDMO Market, by Drug, 2021 - 2033 (USD Million)
  • Table 82 Middle East & Africa Small Molecule API CDMO Market, by Application, 2021 - 2033 (USD Million)
  • Table 83 Middle East & Africa Small Molecule API CDMO Market, by End Use, 2021 - 2033 (USD Million)
  • Table 84 South Africa Small Molecule API CDMO Market, by Drug, 2021 - 2033 (USD Million)
  • Table 85 South Africa Small Molecule API CDMO Market, by Application, 2021 - 2033 (USD Million)
  • Table 86 South Africa Small Molecule API CDMO Market, by End Use, 2021 - 2033 (USD Million)
  • Table 87 Saudi Arabia Small Molecule API CDMO Market, by Drug, 2021 - 2033 (USD Million)
  • Table 88 Saudi Arabia Small Molecule API CDMO Market, by Application, 2021 - 2033 (USD Million)
  • Table 89 Saudi Arabia Small Molecule API CDMO Market, by End Use, 2021 - 2033 (USD Million)
  • Table 90 UAE Small Molecule API CDMO Market, by Drug, 2021 - 2033 (USD Million)
  • Table 91 UAE Small Molecule API CDMO Market, by Application, 2021 - 2033 (USD Million)
  • Table 92 UAE Small Molecule API CDMO Market, by End Use, 2021 - 2033 (USD Million)
  • Table 93 Kuwait Small Molecule API CDMO Market, by Drug, 2021 - 2033 (USD Million)
  • Table 94 Kuwait Small Molecule API CDMO Market, by Application, 2021 - 2033 (USD Million)
  • Table 95 Kuwait Small Molecule API CDMO Market, by End Use, 2021 - 2033 (USD Million)
  • Table 96 Oman Small Molecule API CDMO Market, by Drug, 2021 - 2033 (USD Million)
  • Table 97 Oman Small Molecule API CDMO Market, by Application, 2021 - 2033 (USD Million)
  • Table 98 Oman Small Molecule API CDMO Market, by End Use, 2021 - 2033 (USD Million)
  • Table 99 Qatar Small Molecule API CDMO Market, by Drug, 2021 - 2033 (USD Million)
  • Table 100 Qatar Small Molecule API CDMO Market, by Application, 2021 - 2033 (USD Million)
  • Table 101 Qatar Small Molecule API CDMO Market, by End Use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market Research Process
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 Market Formulation & Validation
  • Fig. 6 Commodity Flow Analysis
  • Fig. 7 Value-Chain-Based Sizing & Forecasting
  • Fig. 8 QFD Model Sizing & Forecasting
  • Fig. 9 Bottom-up approach
  • Fig. 10 Market Snapshot
  • Fig. 11 Segment Snapshot 1
  • Fig. 12 Segment Snapshot 2
  • Fig. 13 Competitive Landscape Snapshot
  • Fig. 14 Parent market outlook, 2025 (USD Billion)
  • Fig. 15 Ancillary market outlook, 2025 (USD Billion)
  • Fig. 16 Small Molecule API CDMO Market Dynamics
  • Fig. 17 Porter's Five Forces Analysis
  • Fig. 18 PESTEL Analysis
  • Fig. 19 Small Molecule API CDMO Market: Drug Outlook And Key Takeaways
  • Fig. 20 Small Molecule API CDMO Market: Drug Movement Analysis
  • Fig. 21 Innovators Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • Fig. 22 Generics Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • Fig. 23 Small Molecule API CDMO Market: Application Outlook And Key Takeaways
  • Fig. 24 Small Molecule API CDMO Market: Application Movement Analysis
  • Fig. 25 Cardiovascular Diseases Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • Fig. 26 Oncology Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • Fig. 27 Respiratory Disorders Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • Fig. 28 Neurology Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • Fig. 29 Metabolic Disorders Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • Fig. 30 Infectious Diseases Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • Fig. 31 Others Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • Fig. 32 Small Molecule API CDMO Market: End Use Outlook And Key Takeaways
  • Fig. 33 Small Molecule API CDMO Market: End Use Movement Analysis
  • Fig. 34 Pharmaceutical Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • Fig. 35 Small Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • Fig. 36 Medium Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • Fig. 37 Large Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • Fig. 38 Biotechnology Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • Fig. 39 Small Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • Fig. 40 Medium Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • Fig. 41 Large Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • Fig. 42 Regional Marketplace: Key Takeaways
  • Fig. 43 North America Small Molecule API CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 44 Key country dynamics
  • Fig. 45 U.S. Small Molecule API CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 46 Key country dynamics
  • Fig. 47 Canada Small Molecule API CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 48 Key country dynamics
  • Fig. 49 Mexico Small Molecule API CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 50 Europe Small Molecule API CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 51 Key country dynamics
  • Fig. 52 UK Small Molecule API CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 53 Key country dynamics
  • Fig. 54 Germany Small Molecule API CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 55 Key country dynamics
  • Fig. 56 France Small Molecule API CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 57 Key country dynamics
  • Fig. 58 Italy Small Molecule API CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 59 Key country dynamics
  • Fig. 60 Spain Small Molecule API CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 61 Key country dynamics
  • Fig. 62 Denmark outsourcing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 63 Key country dynamics
  • Fig. 64 Sweden outsourcing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 65 Key country dynamics
  • Fig. 66 Norway outsourcing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 67 Asia Pacific Small Molecule API CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 68 Key country dynamics
  • Fig. 69 Japan Small Molecule API CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 70 Key country dynamics
  • Fig. 71 China Small Molecule API CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 72 Key country dynamics
  • Fig. 73 India Small Molecule API CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 74 Key country dynamics
  • Fig. 75 Thailand Small Molecule API CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 76 Key country dynamics
  • Fig. 77 South Korea Small Molecule API CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 78 Key country dynamics
  • Fig. 79 Australia Small Molecule API CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 80 Latin America Small Molecule API CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 81 Key country dynamics
  • Fig. 82 Brazil Small Molecule API CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 83 Key country dynamics
  • Fig. 84 Argentina Small Molecule API CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 85 MEA Small Molecule API CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 86 Key country dynamics
  • Fig. 87 South Africa Small Molecule API CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 88 Key country dynamics
  • Fig. 89 Saudi Arabia Small Molecule API CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 90 Key country dynamics
  • Fig. 91 UAE Small Molecule API CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 92 Key country dynamics
  • Fig. 93 Kuwait Small Molecule API CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 94 Key country dynamics
  • Fig. 95 Oman Small Molecule API CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 96 Key country dynamics
  • Fig. 97 Qatar Small Molecule API CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)